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Pancreatic ductal adenocarcinoma (PDAC) is a particularly challenging cancer, with very low 
5-year survival rates. This low survival rate is linked to late stage diagnosis, associated with 
the lack of approved biomarkers. One approach that is receiving considerable attention is the 
use of volatile organic compounds (VOCs) that emanate from biological waste as biomarkers 
for disease. In this study, we used urine as our biological matrix and two VOC analysis 
platforms: gas chromatography – ion mobility spectrometry (GC-IMS) and GC time-of-flight 
mass spectrometry (GC-TOF-MS). We measured the urinary headspace of samples from 
patients with PDAC, chronic pancreatitis (CP) and healthy controls. In total, 123 samples were 
tested from these groups. Results indicate that both GC-IMS and GC-TOF-MS were able to 
discriminate PDAC from healthy controls with high confidence and an AUC (area under the 
curve) in excess of 0.85. However, both methods struggled to separate CP from PDAC, with 
the best result of AUC 0.58. This indicates that both conditions produce similar biomarkers in 
the urinary headspace. Chemical identification suggests that 2,6-dimethyl-octane, nonanal, 4-
ethyl-1,2-dimethyl-benzene and 2-pentanone play an important role in separating between 
groups. Therefore, both techniques validate this approach in identifying subjects for further 








Cancer is currently the second leading cause of death globally, accounting for around 9.6 
million deaths (1 in 6) in 2018. This trend is likely to continue, with the latest projections 
suggesting that annual cancer-related deaths will increase to 13 million by 2030 [1]. Thus the 
burden of cancer will continue to exert tremendous physical, emotional and financial strain on 
individuals, families, communities and healthcare systems. Pancreatic cancer is the eighth 
leading cause of cancer death worldwide (around 400,000 deaths) [1]. The most frequent 
pancreatic malignant tumour is pancreatic ductal adenocarcinoma (PDAC). PDAC represents 
around 85% of all reported pancreatic cancer cases [2]. It stubbornly resists our attempts to 
successfully target with current therapies, which are reflected in patient 5-year survival rates at 
below 8% [3]. This exceptionally poor prognosis is largely due to late diagnosis. However, if 
the disease is detected when the cancer is at an early stage (< 2 cm diameter) and still confined 
to the pancreas, the survival rate can increase, potentially up to 75% [4,5]. Current pancreatic 
cancer diagnostic techniques rely on imaging (e.g. CT and MRI), endoscopy ultrasonography 
and biopsy for grading tumour histology [6]. Unfortunately, these techniques are not very 
effective at detecting tumours that are smaller than 2 cm in diameter [7].   
 
An alternative cancer diagnosis approach, currently attaining traction, is the use of volatile 
organic compounds (VOCs) that emanate from biological waste, be it breath, stool, urine or 
sweat [8,9].  The initial interest in the detection of VOCs for cancer has been driven by early 
reports on the ability of canines to identify cancer in their owners [10]. Since then, a number 
of studies have demonstrated that VOC profiles reflect metabolic changes in response to 
inflammation, necrosis, cancer development and microbiota alterations [11]. This concept has 
been taken forward through the use of a variety of analytical platforms, from high-end gas 
chromatography – mass spectrometry (GC-MS) to lower-cost/portable technologies that mimic 
the biological olfactory system (electronic noses) (reviewed in [12,13]). To this end, VOCs 
have been reported, by our and other groups, to be promising biomarkers for several cancers 
[14–17].  
 
One of the simplest biological material to access is urine. This is a far less complex matrix, 
compared to blood, and can be collected in large volumes, completely non-invasively and with 
high patient acceptability (far higher than faeces). Our group have hypothesised that 
biomarkers for PDAC exist in urine and that they have the potential to be used as an early 
detection and screening tool for patients at risk of this malignancy. To test this hypothesis, we 
previously investigated the urinary VOCs using a Lonestar FAIMS (field asymmetric ion 
mobility spectrometry) (Owlstone Medical, Cambridge, UK), which showed good 
discriminatory performance between PDAC and healthy control samples [18]. However, the 
FAIMS is unable to identify any specific biomarkers and the Lonestar unit is operated 
manually, testing one sample at a time, making its use more challenging in a clinical setting. 
Here we report on our attempts to further evaluate VOCs for the detection of PDAC, with a 
focus on identifying specific biomarkers of the disease and to evaluate a second gas analytical 
platform that is more appropriate for use in a clinical setting. 
 
2. Materials and Methods 
 
2.1 Urine Samples 
 
Urine specimens utilised in this study were obtained from Barts Pancreas Tissue Bank, after 
patient consent and with ethical approval (reference number 13/SC/0593). The midstream urine 
samples were collected in 50 mL sterile containers and were kept at +40C before freezing within 
four hours. In large majority of cases the containers were filled with urine with no or little 
headspace. All samples were stored at -80°C according to standard operating procedures 
compliant with tissue bank requirements under Human Tissue Act 2004. This study included 
patients with PDAC, chronic pancreatitis (CP) and healthy controls. Chronic pancreatitis is an 
inflammation of the pancreas and is a condition that is associated with an increased risk of 
developing pancreatic cancer [19].  This diagnostic group was included in the study to evaluate 
whether urinary analysis could be used to distinguish such patients at risk from the healthy and 
PDAC groups. In total, 123 urine samples were analysed: 33 healthy, 45 CP and 45 PDAC. 
The basic demographic information for the subject cohorts is summarised in Table 1.  
 
2.2 Measurement Instrumentation 
 
The urine samples were analysed using two analytical methods: gas chromatography – ion 
mobility spectrometry (GC-IMS) and by gas chromatography time-of-flight mass spectrometry 
(GC-TOF-MS). The GC-IMS system used was a G.A.S. GC-IMS (Dortmund, Germany) and 
was fitted with a 30 m, 0.32 mm inner diameter (ID) SE-54 column (CS Chromatographie 
Service, Langerwehe, Germany). The GC-IMS is formed of a GC pre-separator, followed by a 
drift tube IMS as the detector. In use, once a sample is injected into the device, the GC 
selectively slows down molecules based on the interaction between the molecule and the GC 
columns retentive coating, as they pass through the column, and thus temporally separates them 
as they exit. These enter a drift-tube, where the molecules are ionised (in this case, using a low-
radiation tritium source). The ionised sample is then passed through a drift tube, to which a 
known electric field is applied to propel the ions along it. Against the flow of ions, a buffer gas 
is passed that collides with the ions. Large ions have many collisions and slow down, whilst 
small ions have less collisions and maintain their momentum. Therefore, the time taken for 
ions to be detected is based on their interaction with the electric field and the buffer gas [20].  
 
GC-TOF-MS works in a similar way to traditional GC-MS methods, but instead of filtering 
ions by mass, the TOF utilises ‘time of flight’ and analyses all ions present. The GC-TOF-MS 
system consists of a TRACE 1300 GC (Thermo Fisher Scientific, Loughborough, UK), 
combined with a BenchTOF-HD TOF-MS (Markes Intl., Llantrisant, UK). The GC column 
used was a 20 m, 0.18 mm ID, Rxi-624Sil MS column (Thames Restek, Saunderton, UK). This 
system also includes a high-throughput autosampler and a thermal desorption unit, ULTRA-xr 
and UNITY-xr, respectively (both from Markes Intl.). As with a GC-MS system, samples are 
injected into the GC column. Compounds within a sample can be separated due to the 
interaction of the molecules with the stationary phase of the column (as with GC-IMS). The 
separated molecules leave the column at different times, giving a retention time. The molecules 
are then ionised, and the resultant ions are detected by the mass spectrometer. In a GC-TOF-
MS system, once the sample has passed through the GC column, the separated molecules are 
ionised and enter the TOF ‘flight box’. TOF-MS works on the principle that when molecules 
are exposed to a pre-determined amount of energy, larger, heavier ions will take longer than 
smaller, lighter ions to travel a set distance. The addition of the TOF into the GC-MS method 
allows for further separation of the ions present in a sample, increasing the sensitivity of the 
method [21].  
 
2.3 GC-IMS Measurements 
 
For GC-IMS measurements, we have developed a standard method for testing urine samples, 
where we have optimised the sample temperature, method temperatures and flow rates to 
maximise information content and produce reproducible results. The urine samples were 
shipped on dry ice to the University of Warwick and were stored at -20°C. Prior to analysis, 
the samples were thawed for four hours at room temperature. 5 ml samples of urine were 
aliquoted into 20 ml glass vials and sealed with a crimp cap and septa. Once sealed, the samples 
were agitated and heated to 40°C for 10 min. For sampling, a sterile needle, attached to the 
heated sample inlet of the GC-IMS, was inserted into the sample headspace, through the septa. 
The GC-IMS sampled 2 ml of the headspace for analysis. The sampling and analysis were 
performed using the following settings: GC flow rate = 20 ml/min, drift tube flow rate = 150 
ml/min, IMS temperature = 45°C, GC temperature (fixed) = 45°C, Sample loop = 45°C and 
inlet injector = 45°C. The analysis time for each sample was 8 min. For quality control, all flow 
rates, method temperatures and RIP magnitude and location were checked for each sample, to 
be within unit tolerances. Furthermore, the output obtained from each sample was visually 
checked to ensure that they contained the expected level of information content. Finally, air 
blanks were run either side of a test batch of samples (20 samples) to ensure that there was no 
machine drift  
 
2.4 GC-TOF-MS Measurements 
 
For GC-TOF-MS analysis, urine samples were defrosted as described in section 2.3, with 10 
ml of sample aliquoted into a 20 ml glass vial, which were then sealed with a specially adapted 
septa and crimp cap. A thermal desorption (TD) sorbent tube (C2-AXXX-5149, Markes Intl., 
Llantrisant, UK) was placed through the septa and into the headspace above the urine sample. 
The vial and sorbent tube were then placed into a heater block and heated to 40oC for 1 hour. 
Once completed, the tube was removed from the top of the vial and placed into the autosampler 
for analysis. The ULTRA-xr was set to run with a stand-by split of 150°C with an overlap (this 
allows the auto-sampler to reduce the overall run time), a GC run-time of 30 min, and a 
minimum carrier pressure of 5 psi. For each sample there is a pre-purge of 1 min. The tube was 
desorbed for 10 min at 250°C, with the trap purge time set to 1 min, and the trap cooled to -
30°C. The trap was then purged for 3 min at a temperature of 300°C. The GC-TOF-MS method 
measured masses from 45 to 500 atu (atomic mass units). The transfer line and ion source are 
both heated to 250°C, with an ionisation voltage of -70.000V. The GC oven was heated to 
280°C for 25 min. Upon completion of the GC-TOF-MS run-time, peaks were identified using 
NIST list 2016. For quality control, the machine was calibrated in line with the manufacturer’s 
recommendation. The method used was developed using healthy control urine samples from a 
previous study, where parameters were optimised to maximise separation and chemical 
content. 
 
2.5 Data Analysis 
 
GC-IMS generate very high-dimensional data (typically 11 million data points per sample). 
Therefore, to aid in data analysis, pre-processing steps were applied to reduce its 
dimensionality. As the chemical information on the output is located around the central region 
of the output data, we can crop this section and discard the rest. The size of the crop area is 
chosen through visual observation of the data and the same crop values are used for all the data. 
The second step is to delete the reactant ion peak (RIP), which is output when there are no 
chemicals present. This is undertaken by selecting a line where there is no chemical information 
(though contains the RIP) and subtracting this from the rest of the data. A small threshold is 
added to this value to remove the background noise, which was selected manually as applied 
the same to all the data. These steps reduce the number of data points from around 11 million 
to 10,000, without losing any volatile information. 
 
The data was then analysed using a 10-fold cross validation, using our custom developed 
pipeline, created in ‘R’ (version 3.6.1). In this case, the data is divided into two groups, with 
90% of the data being used as a training set and 10% is used as a test set. To identify features 
(data points) that hold discriminatory information, a rank-sum test was undertaken and features 
with the lowest p-values are selected from training. These features are used for training three 
different classifiers, specifically random forest (RF), Gaussian process (GP), and sparse logistic 
regression (SLR). We have previously used these successfully in a range of medical VOC 
studies [22–24]. Using the developed model, the test samples are then classified and a 
probability for each test sample is created. This process was repeated 10 times so that all the 
samples were classified as test samples. Using the resultant probabilities, statistical parameters, 
including area under the curve (AUC), sensitivity, specificity, negative predictive value and 
positive predictive value are calculated.  
 
The GC-TOF-MS analysis was undertaken using a similar approach. In this case, each 
identified chemical was used as a feature and the abundance as the magnitude of the feature. 
This was processed in the same way as described above, but without the rank-sum test as the 
data already had low dimensionality. From this process, we are also able to identify which 
features/chemicals hold discriminatory information. 
 
3. Results  
 
A typical output plot from the GC-IMS and GC-TOF-MS are shown in Figure 1 and Figure 2, 
respectively. For the GC-IMS, the background is blue, with the RIP line being red (which is 
always present). The chemicals are seen as white/red areas. The colour represents the intensity 
of the chemical. Three different analyses were undertaken comparing PDAC, healthy and CP 
groups. GC-IMS analysis indicated that there were differences between the three groups. The 
three classifiers resulted in very similar data, with the best results shown in Table 2 and the 
complete data in supplementary table TS1. The PDAC ROC curves are shown in Figure 3. The 
results indicate that GC-IMS (sensitivity 84%, specificity 94%, p-value >0.0001) can separate 
PDAC from healthy controls. However, the separation between PDAC and CP group is not as 
pronounced (sensitivity 51%, specificity 73%, p-value 0.11), indicating that the same 
biomarkers are involved in both conditions. 
 
We undertook the same analytical methods for the data analysed by GC-TOF-MS. In this case, 
the statistical results are shown in Table 3, with the PDAC ROC curves in Figure 4. Here, we 
were also able to separate PDAC from healthy controls (sensitivity 72%, specificity 96%, p-
value >0.0001). However, when comparing CP to PDAC (sensitivity 38%, specificity 88%, p-
value 0.28), our results did not show a significant difference.  
 
From the analysis, we were able to identify chemicals that held discriminatory properties. 15 
chemicals for each comparison were identified. From this list, a rank-sum test of each 
chemical/features was undertaken and the top three chemicals for each comparison are listed 
in Table 4, with the complete set in supplementary information TS3. As shown, we have 
identified common chemicals from each of the analyses, with 2,6-dimethyl-octane, 2-
pentanone, nonanal and 4-ethyl-1,2-dimethyl-benzene being most frequent.  
 
4. Discussion  
 
In a recent review paper, Bax et al. [11] evaluated and compared cancer biomarker trends in 
urine as a new diagnostic pathway. Five studies [25–29] investigating urinary pancreatic cancer 
biomarkers were included in the review. The employed technologies were nuclear magnetic 
resonance (NMR) spectroscopy and gel electrophoresis liquid chromatography-tandem mass 
spectrometry (GeLC-MS/MS). To the best of our knowledge, this was the first urinary study 
to utilise GC-IMS and GC-TOF-MS technologies to investigate PDAC, CP and healthy 
controls. Both the GC-IMS and GC-TOF-MS were able to separate PDAC from healthy 
controls with good sensitivity and specificity, with the GC-IMS outperforming the GC-TOF-
MS. Only the GC-IMS was able to accurately separate CP from controls, whilst the GC-TOF-
MS showed inferior results. Comparing PDAC with CP for both methods, the AUCs were 
around 0.6, showing a modest diagnostic performance. This limited ability to separate these 
two groups, could well have impacted the overall diagnostic performance of PDAC vs all other 
samples, with both methods having an AUC of around 0.7. In statistical results, these variations 
are likely to be associated with the choice of column between the two analytical platforms and 
the sample capture process. The sorbent tubes used for the GC-TOF-MS analysis capture 
analytes from C3 (though more likely C4) and upwards, whilst the GC-IMS is analysing all the 
chemicals through direct headspace injection. This is a limitation of the experimental method, 
where the absorbent tube and trap on the TD unit cannot go below C3 (with C referring to the 
number of carbon atoms). Another difference between the platforms is that the GC-IMS 
molecular detection depends on the proton affinity of the molecule.  However, the overall 
statistical performance was similar. Some of the discriminatory VOCs, identified in this study, 
have been suggested as potential biomarkers in breath or stool for other disease. For example, 
2-pentanone has been found to be associated with several diseases, such as non-alcoholic fatty 
liver disease [30], inflammatory bowel disease (ulcerative colitis and Crohn’s disease) [31,32] 
and lung cancer [33]. Nonanal is a saturated fatty aldehyde formally arising from reduction of 
the carboxy group of nonanoic acid. It has been observed as a discriminatory VOC for other 
cancers, such as ovarian and lung cancer [34,35]. This indicates that some of these compounds 
might be more generic markers of inflammation or illness. As stated above, a limitation of this 
study is that the analytical approaches we have used here may have missed other potential 
biomarkers. For example, biomarkers under C3 could be critical. Only undertaking additional 
experiments with direct headspace injection into a GC-MS or similar technique will allow us 
to identify if such biomarkers exist. Though GC-IMS will measure these chemicals, 
identification is more limited, and it will not detect those molecules with low proton affinity. 
In addition, due to difficulty in obtaining these samples, we were not able to undertake 
extensive optimisation of the sampling conditions for this specific disease and we relied on a 
method we had previously developed for the analysis of urine samples in general. Therefore, 
better diagnostic performance could be achieved in the future if more urine samples could be 
collected. Furthermore, the total number of samples was only 123. In the follow up study, we 
will be analysing more samples, which will enable us to divide the samples into a separate test 




In this paper we investigated the use of urinary headspace volatiles to identify patients suffering 
from PDAC. Urinary headspace was analysed by GC-IMS and GC-TOF-MS, with both 
showing potential in separating PDAC from healthy controls. However, both GC-IMS and GC-
TOF-MS showed only small differences between PDAC and CP, indicating that there is 
commonality between the VOCs produced by both conditions. This is supported by the high 
sensitivity of CP vs healthy controls. Chemical identification suggests that 2,6-dimethyl-
octane, nonanal, 4-ethyl-1,2-dimethyl-benzene and 2-pentanone play an important role in 
separating the data into disease groups or controls. Further work is needed to validate these 
biomarkers in a larger study. However, we believe this approach might hold a potential as a 
completely non-invasive detection tool for pancreatic cancer. 
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Table 1: Demographics of sample groups and cancer stage 
Group Gender (Male:Female) Av. age (range) years Number of subjects (Stage S x Number) 
PDAC 22M:23F 64.1 +/- 10.7 (29-77) 45 (SI x 1; SII x 21; SIII x 20; SIV x 3) 
CP 28M:17F 52.9 +/- 12.2 (21-78) 45 (not applicable) 
Healthy 15:M:18F 49.9 +/- 7.8 (30-66) 33 (not applicable) 
 
  
Table 2: Statistical analysis of GC-IMS data (best results) 
Statistical 
parameter 
PDAC vs All PDAC vs CP PDAC vs Healthy CP vs Healthy 
Best classifier SLR GP SLR GP 
AUC 0.69 (0.58 – 0.79) 0.58 (0.45 – 0.71) 0.88 (0.79 – 0.97) 0.86 (0.77 – 0.95) 
Sensitivity 0.72 (0.56 – 0.85) 0.51 (0.35 – 0.67) 0.84 (0.69 – 0.73) 0.80 (0.64 – 0.91) 
Specificity 0.60 (0.57 – 0.71) 0.73 (0.56 – 0.85) 0.94 (0.79 – 0.99) 0.91 (0.75 – 0.98)  
PPV 0.52 0.67  0.95 0.91 
NPV 0.78 0.58 0.81 0.78 
p-value 4.39 x 10-4 0.11 1.18 x 10-8 9.79 x 10-9 
 
  
Table 3: Statistical analysis of GC-TOF-MS data (best results) 
Statistical 
parameter 
PDAC vs All PDAC vs CP PDAC vs Healthy CP vs Healthy 
Best classifier SLR RF SLR RF 
AUC 0.75 (0.63 – 0.87) 0.55 (0.37 – 0.73) 0.86 (0.75 – 0.97) 0.67 (0.50 – 0.83) 
Sensitivity 0.52 (0.37 – 0.67) 0.38 (0.18 – 0.62) 0.72 (0.51 – 0.88) 0.38 (0.18 – 0.62) 
Specificity 0.96 (0.79 – 1) 0.88 (0.68 – 0.97) 0.96 (0.79 – 1) 0.96 (0.80 – 1.00) 
PPV 0.96 0.73 0.95 0.89 
NPV 0.51 0.62 0.77 0.65 
p-value 3.11 x 10-4 0.28 1.81 x 10-6 2.75 x 10-2 
 
  
Table 4: Chemicals used to separate sample groups. 
PDAC vs CP PDAC vs Healthy CP vs Healthy 
2-pentanone 2,6-dimethyl-octane 2-pentanone 
Nonanal Nonanal Benzene, 1-ethenyl-2-methyl- 
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Figure 1: GC-IMS output of a PDAC urine sample (in colour) 
Figure 2: Typical GC-TOF-MS output of a PDAC urine sample, with example chemicals 
labelled. 
Figure 3: ROC for (a) PDAC vs Healthy and (b) PDAC vs CP using GC-IMS 
Figure 4: ROC for (a) PDAC vs Healthy and (b) PDAC vs CP using GC-TOF-MS 
 
 
 
